Cambridge Investment Research Advisors’s Gain Therapeutics GANX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Hold	568,645	–	–	﹤0.01%	2167
2026 Q1	$1.1M	Hold	568,645	–	–	﹤0.01%	2082
2025 Q4	$1.83M	Buy	568,645 +250,000	+78%	+$667K	﹤0.01%	1610
2025 Q3	$564K	Buy	318,645 +139,145	+78%	+$235K	﹤0.01%	2556
2025 Q2	$323K	Buy	179,500 +120,000	+202%	+$222K	﹤0.01%	2917
2025 Q1	$114K	Buy	59,500 +5,000	+9%	+$11.1K	﹤0.01%	3336
2024 Q4	$118K	Buy	+54,500	New	+$109K	﹤0.01%	3306

Other funds holding GANX

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

BFA

Benedict Financial Advisors Atlanta, Georgia $515M AUM 24.59% 1-Year Est. Return

AWM

Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

HWM

HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Cambridge Investment Research Advisors's GANX Position: Q2 2026 in Review

Cambridge Investment Research Advisors held its Gain Therapeutics (GANX) position steady in Q2 2026 at 568,645 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #2167.

Cambridge Investment Research Advisors first reported a position in GANX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.83M in Q4 2025. 10 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Cambridge Investment Research Advisors held 568,645 shares of Gain Therapeutics worth $1.15M as of Q2 2026.
Cambridge Investment Research Advisors left its Gain Therapeutics share count unchanged in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2167 holding.
Cambridge Investment Research Advisors first reported a position in Gain Therapeutics in Q4 2024 and has held it in 7 quarters since.
Cambridge Investment Research Advisors's Gain Therapeutics position peaked at $1.83M in Q4 2025.
10 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.